Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).
Acute Lymphoblastic Leukemia|ALL, Childhood|ALL
DRUG: Ruxolitinib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Vincristine|DRUG: Pegaspargase|DRUG: Rituximab|DRUG: Methotrexate (Intrathecal Administration)|DRUG: Methotrexate (Intravenous Administration)|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Thioguanine|DRUG: Methotrexate Oral Product
Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given, Determined by rate of side effects seen when combination is given, 24 weeks
Rate of participants that are minimal residual disease (MRD) negative at end of induction therapy, 4 weeks|Overall survival rate, 2 years|Event-free survival rate, 2 years
This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).